A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Public ClinicalTrials.gov record NCT06095089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
Study identification
- NCT ID
- NCT06095089
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 355 participants
Conditions and interventions
Conditions
Interventions
- JNJ-78278343 Drug
- JNJ-87189401 Drug
- Apalutamide Drug
- Lutetium Lu-177 Vipivotide Tetraxetan Drug
- JNJ-101556143 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2023
- Primary completion
- Jun 20, 2027
- Completion
- Jun 27, 2028
- Last update posted
- Aug 27, 2026
2023 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Recruiting |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| University Of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| START New Jersey | East Brunswick | New Jersey | 08816 | Recruiting |
| Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York | New York | 10032 | Recruiting |
| Atrium Health Levine Cancer Institute | Charlotte | North Carolina | 28204 | Recruiting |
| Oregon Health And Science University | Portland | Oregon | 97239 | Recruiting |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| South Texas Accelerated Research Therapeutics, LLC (START) | San Antonio | Texas | 78229 | Recruiting |
| Swedish Medical Center | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06095089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06095089 live on ClinicalTrials.gov.